Pulmatrix (PULM) 10-Q 8 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 04, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36199
Entity Registrant Name	PULMATRIX, INC.
Entity Central Index Key	0001574235
Entity Tax Identification Number	46-1821392
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	945 Concord Street
Entity Address, Address Line Two	Suite 1217
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01701
City Area Code	(888)
Local Phone Number	355-4440
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PULM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,652,285

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,782	$ 19,173
Accounts receivable	23	928
Prepaid expenses and other current assets	641	742
Total current assets	11,446	20,843
Property and equipment, net		1,158
Operating lease right-of-use asset		10,309
Long-term restricted cash	10	1,472
Other long-term assets	54	176
Total assets	11,510	33,958
Current liabilities:
Accounts payable	373	1,915
Accrued expenses and other current liabilities	217	947
Operating lease liability		429
Deferred revenue		618
Total current liabilities	590	3,909
Deferred revenue, net of current portion		3,727
Operating lease liability, net of current portion		8,327
Total liabilities	590	15,963
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at September 30, 2024 and December 31, 2023
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at September 30, 2024 and December 31, 2023
Additional paid-in capital	306,090	305,592
Accumulated deficit	(295,170)	(287,597)
Total stockholders’ equity	10,920	17,995
Total liabilities and stockholders’ equity	$ 11,510	$ 33,958

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	3,652,285	3,652,285
Common stock, shares outstanding	3,652,285	3,652,285
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	6,746	6,746
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues	$ 366	$ 1,753	$ 7,803	$ 5,096
Operating expenses:
Research and development	814	3,963	7,160	12,002
General and administrative	2,209	1,729	5,836	5,609
Loss on MannKind Transaction			2,618
Total operating expenses	3,023	5,692	15,614	17,611
Loss from operations	(2,657)	(3,939)	(7,811)	(12,515)
Other income (expense):
Interest income	101	217	394	675
Other expense, net	(31)	(52)	(156)	(198)
Total other income, net	70	165	238	477
Net loss	$ (2,587)	$ (3,774)	$ (7,573)	$ (12,038)
Net loss per share attributable to common stockholders - basic	$ (0.71)	$ (1.03)	$ (2.07)	$ (3.30)
Net loss per share attributable to common stockholders - diluted	$ (0.71)	$ (1.03)	$ (2.07)	$ (3.30)
Weighted average common shares outstanding - basic	3,652,285	3,652,285	3,652,285	3,651,785
Weighted average common shares outstanding - diluted	3,652,285	3,652,285	3,652,285	3,651,785

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022			$ 304,585	$ (273,476)	$ 31,109
Balance, shares at Dec. 31, 2022		3,639,185
Stock-based compensation			296		296
Net loss				(4,448)	(4,448)
Issuance of common stock, net of issuance costs			53		53
Issuance of common stock, net of issuance costs, shares		13,100
Balance at Mar. 31, 2023			304,934	(277,924)	27,010
Balance, shares at Mar. 31, 2023		3,652,285
Balance at Dec. 31, 2022			304,585	(273,476)	31,109
Balance, shares at Dec. 31, 2022		3,639,185
Net loss					(12,038)
Balance at Sep. 30, 2023			305,395	(285,514)	19,881
Balance, shares at Sep. 30, 2023		3,652,285
Balance at Mar. 31, 2023			304,934	(277,924)	27,010
Balance, shares at Mar. 31, 2023		3,652,285
Stock-based compensation			255		255
Net loss				(3,816)	(3,816)
Balance at Jun. 30, 2023			305,189	(281,740)	23,449
Balance, shares at Jun. 30, 2023		3,652,285
Stock-based compensation			206		206
Net loss				(3,774)	(3,774)
Balance at Sep. 30, 2023			305,395	(285,514)	19,881
Balance, shares at Sep. 30, 2023		3,652,285
Balance at Dec. 31, 2023			305,592	(287,597)	17,995
Balance, shares at Dec. 31, 2023		3,652,285
Stock-based compensation			198		198
Net loss				825	825
Balance at Mar. 31, 2024			305,790	(286,772)	19,018
Balance, shares at Mar. 31, 2024		3,652,285
Balance at Dec. 31, 2023			305,592	(287,597)	17,995
Balance, shares at Dec. 31, 2023		3,652,285
Net loss					(7,573)
Balance at Sep. 30, 2024			306,090	(295,170)	10,920
Balance, shares at Sep. 30, 2024		3,652,285
Balance at Mar. 31, 2024			305,790	(286,772)	19,018
Balance, shares at Mar. 31, 2024		3,652,285
Stock-based compensation			103		103
Net loss				(5,811)	(5,811)
Balance at Jun. 30, 2024			305,893	(292,583)	13,310
Balance, shares at Jun. 30, 2024		3,652,285
Stock-based compensation			197		197
Net loss				(2,587)	(2,587)
Balance at Sep. 30, 2024			$ 306,090	$ (295,170)	$ 10,920
Balance, shares at Sep. 30, 2024		3,652,285

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (7,573)	$ (12,038)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	106	96
Amortization of operating lease right-of-use asset	329	1,171
Stock-based compensation	498	757
Loss on disposals	2,618	8
Changes in operating assets and liabilities:
Accounts receivable	905	457
Prepaid expenses and other current assets	101	169
Other long-term assets	122	172
Accounts payable	(1,542)	(481)
Accrued expenses and other current liabilities	(341)	233
Operating lease liability	(333)	(3,383)
Deferred revenue	(4,345)	(1,135)
Net cash used in operating activities	(9,455)	(13,974)
Cash flows from investing activities:
Purchases of property and equipment	(398)	(371)
Net cash used in investing activities	(398)	(371)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		53
Net cash provided by financing activities		53
Net decrease in cash, cash equivalents and restricted cash	(9,853)	(14,292)
Cash, cash equivalents and restricted cash — beginning of period	20,645	37,253
Total cash, cash equivalents and restricted cash	10,792	22,961
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	10,782	21,336
Restricted cash		153
Long-term restricted cash	10	1,472
Supplemental disclosures of non-cash investing and financing information:
Reduction of operating lease right-of-use asset and lease liability upon lease modification	8,423
Purchases of property and equipment not yet paid		664
Operating lease right-of-use asset obtained in exchange for operating lease obligation		$ 9,323

Organization

Organization	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Pulmatrix, Inc. (the “Company”) was incorporated in 2013 as a Delaware corporation. The Company is a clinical-stage biopharmaceutical company focused on the development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE ™ ™

Summary of Significant Accounti

Summary of Significant Accounting Policies and Recent Accounting Standards	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Recent Accounting Standards	2. Summary of Significant Accounting Policies and Recent Accounting Standards Basis of Presentation The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024 (the “Annual Report”). The financial information as of September 30, 2024, and for the three and nine months ended September 30, 2024 and 2023, is unaudited. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. Based on its current operating plan, the Company believes that its cash and cash equivalents as of September 30, 2024, will be adequate to fund its currently anticipated operating expenses for at least twelve months from the date these condensed consolidated financial statements are issued. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company’s planned research and development activities and regulatory activities; commercialize product candidates; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, it will be required to significantly decrease the amount of planned expenditures and may be required to cease operations. In addition, any disruption in the capital markets could make any financing more challenging, and there can be no assurance that Pulmatrix will be able to obtain such financing on commercially reasonable terms or at all. Curtailment of operations would cause significant delays in the Company’s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company. Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements have included, but are not limited to, estimates of future expected costs in order to derive and recognize revenue and estimates related to clinical trial accruals and upfront deposits. Concentrations of Credit Risk Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits. For the three and nine months ended September 30, 2024, revenue from two customers accounted for 100 100 100 Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2024 that had a material effect on its condensed consolidated financial statements. In November 2023, the FASB issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued Accounting Standard Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures As of September 30, 2024, there are no other new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2024
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2024 December 31, 2023 Insurance $ 317 $ 232 Clinical and consulting 72 30 Software and hosting costs 60 108 Other 192 372 Total prepaid expenses and other current assets $ 641 $ 742

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net The Company’s Property and equipment, net, were included in the disposal group as part of the MannKind Transaction (as defined in Note 6, Significant Agreements Schedule of Property and Equipment September 30, 2024 December 31, 2023 Laboratory equipment $ - $ 1,656 Office furniture and equipment - 401 Computer equipment - 237 Capital in progress - 600 Total property and equipment - 2,894 Less accumulated depreciation and amortization - (1,736 ) Property and equipment, net $ - $ 1,158 Depreciation and amortization expense for the nine months ended September 30, 2024 and 2023 was $ 106 96

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities September 30, 2024 December 31, 2023 Legal and patents $ 112 $ 42 Wages and incentives 37 70 Clinical and consulting 12 347 Accrued purchases of property and equipment - 389 Other 56 99 Total accrued expenses and other current liabilities $ 217 $ 947

Significant Agreements

Significant Agreements	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Significant Agreements	6. Significant Agreements Development and Commercialization Agreement with Cipla Technologies LLC (“Cipla”) On April 15, 2019, the Company entered into a Development and Commercialization Agreement (the “Cipla Agreement”) with Cipla for the co-development and commercialization, on a worldwide exclusive basis, of PUR1900, the Company’s inhaled iSPERSE ™ The Company received a non-refundable upfront payment of $ 22.0 ™ Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company shared all other development costs with Cipla that were not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis. Pursuant to the Third Amendment, the Company and Cipla agreed that, during the period commencing on January 6, 2024 and ending July 30, 2024 (the “Wind Down Period”), the Company would complete all Phase 2b activities, assign or license all patents to Cipla and their registration with the appropriate authorities in regions other than the United States, complete a physical and demonstrable technology transfer and secure all data from the Phase 2b study for inclusion in the safety database. The Company shared costs with Cipla during the Wind Down Period in the same proportions in effect with the Second Amendment discussed above, but subject to a maximum reimbursement amount by Cipla as approved by the joint steering committee. The Company completed all Phase 2b activities by the end of the Wind Down Period. The Company is in the process of settling certain final bills with its PUR1900 contractors, which together comprise an immaterial balance recorded within accounts payable as of September 30, 2024. Accounting Treatment The Company originally concluded that because both it and Cipla are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, the Company’s collaboration with Cipla is within the scope of Accounting Standards Codification (“ASC”) 808, Collaborative Arrangements Revenue from Contracts with Customers The Company initially determined the total transaction price to be $ 22.0 12.0 10.0 Revenue is recognized for the Cipla Agreement as the research and development services are provided using an input method, according to the ratio of costs incurred to the total costs expected to be incurred in the future to satisfy the Company’s obligations. In management’s judgment, this input method is the best measure of the transfer of control of the combined performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheets, with amounts expected to be recognized in the next 12 months recorded as current. The Company concluded that the Third Amendment is a contract modification that should be accounted for as part of the existing contract. During the three and nine months ended September 30, 2024, the Company recognized $ 0.3 6.9 1.8 5.1 Agreements with MannKind Corporation (“MannKind”) On May 28, 2024, the Company executed certain agreements with MannKind and the Company’s landlord (collectively, the “MannKind Transaction”), all of which closed during July 2024. The agreements with MannKind included a Bill of Sale and Assignment Agreement (the “Bill of Sale”) with respect to the assignment of the Company’s rental facility at 36 Crosby Drive, Bedford, Massachusetts (the “Bedford Facility”) to MannKind along with the transfer of all leasehold improvements, laboratory equipment and other related personal property. In connection with the assignment of the Bedford Facility, the Company, MannKind and Cobalt Propco 2020, LLC (the “Landlord”) entered into an Amendment to Lease and Consent to Assignment of Lease (the “Lease Assignment Agreement”) pursuant to that certain Lease Agreement, dated as of January 7, 2022 (the “Lease Agreement”), by and between the Company and the Landlord. Pursuant to the Lease Assignment Agreement, MannKind assumed all of the Company’s obligations under the Lease Agreement, including all rent and other payments. In connection with these transactions, the Company and MannKind entered into an Intellectual Property Cross License Agreement (the “Cross License Agreement”). Pursuant to the Cross License Agreement, the Company granted to MannKind (i) an exclusive license to develop, use, manufacture, market, offer and sell iSPERSE formulations of Clofazimine, (ii) an exclusive license to develop, use, manufacture, market, offer and sell formulations of iSPERSE with one more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans, (iii) an exclusive license to develop, use, manufacture, market, offer and sell iSPERSE formulations of insulin, (iv) a non-exclusive license to develop, use, manufacture, market, offer and sell formulations of iSPERSE with one more active pharmaceutical ingredients for the treatment of endocrine disease in humans, and (v) a non-exclusive license to develop, use, manufacture, market, offer and sell formulations of iSPERSE with one more active pharmaceutical ingredients for the treatment of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans (collectively, the “Out-License”). Additionally, pursuant to the Cross License Agreement, MannKind granted to the Company (i) the exclusive right to develop, use, manufacture, market, offer and sell its single-use disposable dry powder inhaler (including all modifications or improvement thereto made by or on behalf of the Company, the “Cricket Device”) for the inhaled delivery of dihydroergotamine in any formulation whatsoever, including the Company’s PUR3100 treatment of acute migraine and (ii) a non-exclusive license to develop, use, manufacture, market, offer and sell the Cricket Device for the inhaled delivery of one more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease in humans (collectively, the “In-License”). Additionally, pursuant to the Master Services Agreement, by and between the Company and MannKind, MannKind shall provide certain development services to the Company, including but not limited to, activities to develop a dry powder formulation of the active pharmaceutical ingredient that the Company provides to MannKind for oral inhalation using iSPERSE. To maintain continuity of iSPERSE platform knowledge, MannKind hired certain members of the Company’s research and development staff in July 2024. Accounting Treatment The Company determined that the MannKind Transaction represents a combined agreement for accounting purposes, as the individual components have the same overall commercial objectives and the consideration under each component is dependent on the other components. The consideration due to the Company in the MannKind Transaction consists solely of the non-cash consideration in the form of the In-License. The fair value of the non-cash consideration received should be allocated to the other components of the MannKind Transaction to determine the consideration received for the other components. The Company determined that the fair value of the In-License is immaterial given that adequate alternative inhaler devices are already available on the market (and indeed, the Company has already established use of another third-party inhalation device in their PUR3100 Phase 1 trial that performed well as a DHE delivery device as reported in a peer-reviewed publication), and considering optional purchases of Cricket Devices are at market prices. Accordingly, the consideration allocated to other components of the MannKind Transaction was immaterial. During the three months ended June 30, 2024, the Company accounted for the Lease Assignment Agreement upon execution as a lease modification that reduced the lease term to the assignment date in July 2024. Accordingly, the Company remeasured its operating lease liability as of the modification date to reflect the decrease in fixed lease payments, with the amount of the remeasurement, $ 8.4 The Company determined that its operating lease right-of-use asset and property and equipment subject to the Bill of Sale represented a disposal group that became held for sale during the second quarter of 2024 and remained classified as held for sale as of June 30, 2024. The Company recorded a full write-down of the disposal group’s carrying value as of June 30, 2024, in the amount of $ 2.6 Concurrent with the closing of the MannKind Transaction, the Company terminated and MannKind hired the majority of the Company’s research and development employees, representing approximately two-thirds of the Company’s workforce at the time. The Company agreed to provide termination benefits to these employees, which has been fully paid as of September 30, 2024.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Common Stock	7. Common Stock In May 2021, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright and Co., LLC (“HCW”) to act as the Company’s sales agent with respect to the issuance and sale of up to $ 20.0 the Company sell its common stock in a registered primary offering using Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month period so long as its public float remains below $ 75,000,000 20,000,000 Sales of common stock under the Sales Agreement are made pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on May 17, 2024, and subsequently declared effective on May 30, 2024 (File No. 333-279491), and a related prospectus. HCW acts as the Company’s sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Capital Market (“Nasdaq”). If expressly authorized by the Company, HCW may also sell the Company’s common stock in privately negotiated transactions. There is no specific date on which the ATM Offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of the ATM Offering in an escrow, trust or similar account. HCW is entitled to compensation at a fixed commission rate of 3.0 During the nine months ended September 30, 2024, no

Warrants

Warrants	9 Months Ended
	Sep. 30, 2024
Warrants
Warrants	8. Warrants There were no 227,120 39.03 Schedule of Warrants Outstanding Adjusted Number of Shares Issue Date Exercise Price Expiration Date Outstanding Exercisable December 17, 2021 $ 14.99 December 15, 2026 36,538 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 281,047 February 16, 2021 $ 49.99 February 11, 2026 65,003 65,003 August 7, 2020 $ 35.99 July 14, 2025 90,743 90,743 August 7, 2020 $ 44.99 July 14, 2025 10,939 10,939 July 23, 2020 $ 35.99 July 14, 2025 77,502 77,502 July 13, 2020 $ 44.99 July 14, 2025 21,846 21,846 July 13, 2020 $ 35.99 July 14, 2025 334,800 334,800 June 15, 2015 $ 1,509.99 Five years after milestone achievement 15,955 - Total 934,373 918,418

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	9. Stock-based Compensation The Company sponsors the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the “Incentive Plan”). As of September 30, 2024, the Incentive Plan provided for the grant of up to 818,936 564,209 8 The following table summarizes stock option activity during the nine months ended September 30, 2024: Schedule of Stock Option Activity Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — January 1, 2024 344,306 $ 20.92 7.54 $ - Forfeited or expired (93,409 ) $ 5.54 Outstanding — September 30, 2024 250,897 $ 26.65 6.39 $ - Exercisable — September 30, 2024 241,413 $ 27.45 6.32 $ - Subsequent to September 30, 2024, but before the date these condensed consolidated financial statements were issued, options to purchase up to 216,851 26.04 No The following table presents total stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023: Schedule of Stock-based Compensation Expenses 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 3 $ 57 148 188 General and administrative 194 149 350 569 Total stock-based compensation expense $ 197 $ 206 498 757

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Research and Development Activities The Company contracts with various other organizations to conduct research and development activities, including clinical trials. The scope of the services under contracts for research and development activities may be modified and the contracts, subject to certain conditions, may generally be cancelled by the Company upon written notice. In some instances, the contracts, subject to certain conditions, may be cancelled by the third party. As of September 30, 2024, the Company had no material noncancellable commitments not expected to be reimbursed under the Cipla Agreement. Legal Proceedings In the ordinary course of its business, the Company may be involved in various legal proceedings involving contractual and employment relationships, patent or other intellectual property rights, and a variety of other matters. The Company is not aware of any pending legal proceedings that would reasonably be expected to have a material impact on the Company’s financial position or results of operations.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	11. Leases New Corporate Headquarters The Company has limited leasing activities as a lessee which are primarily related to its corporate headquarters, which were relocated during the third quarter of 2023 and again during the third quarter of 2024. In June 2024, the Company entered into a short-term lease agreement for its new headquarters at 945 Concord Street, Framingham, Massachusetts. No lease liability or right-of-use asset has been recorded for this short-term lease, and the short-term lease cost associated with this lease is immaterial. Previous Headquarters On May 28, 2024, as part of the MannKind Transaction (see further discussion in Note 6, Significant Agreements 8.4 Following the closing of the MannKind Transaction, $ 1.4 The components of lease expense for the Company for the three and nine months ended September 30, 2024 and 2023 were as follows: Schedule of Components of Lease Expenses 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Lease cost Fixed lease cost $ - $ 553 $ 678 $ 1,349 Variable lease cost 8 203 214 484 Total lease cost $ 8 $ 756 $ 892 $ 1,833 Other information Cash paid for amounts included in the measurement of lease liabilities $ 24 $ 2,699 $ 681 $ 3,562 Weighted-average remaining lease term - 10.2 Weighted-average discount rate - 11.00 %

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The Company had no Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance was recorded as of September 30, 2024 and December 31, 2023. The Company applies ASC 740, Income Taxes

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing the weighted-average number common shares outstanding during the period, after taking into consideration any potentially dilutive effects from outstanding stock options or warrants. Basic and diluted net loss per share were the same for the three and nine months ended September 30, 2024 and 2023, as the effect of potentially dilutive securities would have been anti-dilutive. The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an anti-dilutive impact: Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding Three and Nine Months Ended September 30, 2024 2023 Options to purchase common stock 250,897 364,975 Warrants to purchase common stock 934,373 1,161,493 Total options and warrants to purchase common stock 1,185,270 1,526,468

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events The Company has completed an evaluation of all subsequent events after the balance sheet date of September 30, 2024 through the date the condensed consolidated financial statements were issued to ensure that the condensed consolidated financial statements include appropriate disclosure of events both recognized in the condensed consolidated financial statements as of September 30, 2024, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. The Company has concluded that no subsequent events have occurred that require disclosure, except as disclosed within the condensed consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Recent Accounting Standards (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024 (the “Annual Report”). The financial information as of September 30, 2024, and for the three and nine months ended September 30, 2024 and 2023, is unaudited. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. Based on its current operating plan, the Company believes that its cash and cash equivalents as of September 30, 2024, will be adequate to fund its currently anticipated operating expenses for at least twelve months from the date these condensed consolidated financial statements are issued. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company’s planned research and development activities and regulatory activities; commercialize product candidates; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, it will be required to significantly decrease the amount of planned expenditures and may be required to cease operations. In addition, any disruption in the capital markets could make any financing more challenging, and there can be no assurance that Pulmatrix will be able to obtain such financing on commercially reasonable terms or at all. Curtailment of operations would cause significant delays in the Company’s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.
Use of Estimates	Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements have included, but are not limited to, estimates of future expected costs in order to derive and recognize revenue and estimates related to clinical trial accruals and upfront deposits.
Concentrations of Credit Risk	Concentrations of Credit Risk Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits. For the three and nine months ended September 30, 2024, revenue from two customers accounted for 100 100 100
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2024 that had a material effect on its condensed consolidated financial statements. In November 2023, the FASB issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued Accounting Standard Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures As of September 30, 2024, there are no other new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Prepaid Expenses And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2024 December 31, 2023 Insurance $ 317 $ 232 Clinical and consulting 72 30 Software and hosting costs 60 108 Other 192 372 Total prepaid expenses and other current assets $ 641 $ 742

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment September 30, 2024 December 31, 2023 Laboratory equipment $ - $ 1,656 Office furniture and equipment - 401 Computer equipment - 237 Capital in progress - 600 Total property and equipment - 2,894 Less accumulated depreciation and amortization - (1,736 ) Property and equipment, net $ - $ 1,158

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities September 30, 2024 December 31, 2023 Legal and patents $ 112 $ 42 Wages and incentives 37 70 Clinical and consulting 12 347 Accrued purchases of property and equipment - 389 Other 56 99 Total accrued expenses and other current liabilities $ 217 $ 947

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Warrants
Schedule of Warrants Outstanding	Schedule of Warrants Outstanding Adjusted Number of Shares Issue Date Exercise Price Expiration Date Outstanding Exercisable December 17, 2021 $ 14.99 December 15, 2026 36,538 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 281,047 February 16, 2021 $ 49.99 February 11, 2026 65,003 65,003 August 7, 2020 $ 35.99 July 14, 2025 90,743 90,743 August 7, 2020 $ 44.99 July 14, 2025 10,939 10,939 July 23, 2020 $ 35.99 July 14, 2025 77,502 77,502 July 13, 2020 $ 44.99 July 14, 2025 21,846 21,846 July 13, 2020 $ 35.99 July 14, 2025 334,800 334,800 June 15, 2015 $ 1,509.99 Five years after milestone achievement 15,955 - Total 934,373 918,418

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table summarizes stock option activity during the nine months ended September 30, 2024: Schedule of Stock Option Activity Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — January 1, 2024 344,306 $ 20.92 7.54 $ - Forfeited or expired (93,409 ) $ 5.54 Outstanding — September 30, 2024 250,897 $ 26.65 6.39 $ - Exercisable — September 30, 2024 241,413 $ 27.45 6.32 $ -
Schedule of Stock-based Compensation Expenses	The following table presents total stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023: Schedule of Stock-based Compensation Expenses 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 3 $ 57 148 188 General and administrative 194 149 350 569 Total stock-based compensation expense $ 197 $ 206 498 757

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of Components of Lease Expenses	The components of lease expense for the Company for the three and nine months ended September 30, 2024 and 2023 were as follows: Schedule of Components of Lease Expenses 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Lease cost Fixed lease cost $ - $ 553 $ 678 $ 1,349 Variable lease cost 8 203 214 484 Total lease cost $ 8 $ 756 $ 892 $ 1,833 Other information Cash paid for amounts included in the measurement of lease liabilities $ 24 $ 2,699 $ 681 $ 3,562 Weighted-average remaining lease term - 10.2 Weighted-average discount rate - 11.00 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding	The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an anti-dilutive impact: Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding Three and Nine Months Ended September 30, 2024 2023 Options to purchase common stock 250,897 364,975 Warrants to purchase common stock 934,373 1,161,493 Total options and warrants to purchase common stock 1,185,270 1,526,468

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Recent Accounting Standards (Details Narrative) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue from Contract with Customer Benchmark [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk percentage	100%		100%
Revenue from Contract with Customer Benchmark [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage		100%		100%
Accounts Receivable [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk percentage			100%		100%

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid Expenses And Other Current Assets
Insurance	$ 317	$ 232
Clinical and consulting	72	30
Software and hosting costs	60	108
Other	192	372
Total prepaid expenses and other current assets	$ 641	$ 742

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 2,894
Less accumulated depreciation and amortization		(1,736)
Property and equipment, net		1,158
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		1,656
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		401
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		237
Capital in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 600

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 106	$ 96

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Legal and patents	$ 112	$ 42
Wages and incentives	37	70
Clinical and consulting	12	347
Accrued purchases of property and equipment		389
Other	56	99
Total accrued expenses and other current liabilities	$ 217	$ 947

Significant Agreements (Details

Significant Agreements (Details Narrative) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Product Liability Contingency [Line Items]
Agreement description					Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company shared all other development costs with Cipla that were not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.
Transaction cost	$ 22,000				$ 22,000
Revenue	366		$ 1,753		7,803	$ 5,096
Disposal of carrying value				$ 2,600	(2,618)	(8)
Cipla Agreement [Member] | Cipla Technologies LLC [Member]
Product Liability Contingency [Line Items]
Proceeds from related party debt					22,000
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Research and Development Service [Member]
Product Liability Contingency [Line Items]
Transaction cost	12,000				12,000
Revenue	300		$ 1,800		6,900	$ 5,100
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Irrevocable License [Member]
Product Liability Contingency [Line Items]
Transaction cost	$ 10,000				$ 10,000
Lease Assignment Agreement [Member]
Product Liability Contingency [Line Items]
Decrease in right-of-use asset		$ 8,400

Common Stock (Details Narrative

Common Stock (Details Narrative) - H.C.Wainwright and Co., LLC [Member] - Sale Agreement [Member] - USD ($)	1 Months Ended	9 Months Ended
	May 31, 2021	Sep. 30, 2024
Subsidiary, Sale of Stock [Line Items]
Commission percentage	3%
Number of shares issued in transaction		0
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 20,000,000
Description of stock transaction	the Company sell its common stock in a registered primary offering using Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month period so long as its public float remains below $75,000,000. Therefore, the amount that may be able to be raised using the ATM Offering will be significantly less than $20,000,000, until such time as the Company’s public float held by non-affiliates exceeds $75,000,000.
Public float	$ 75,000,000
Maximum [Member] | ATM Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 20,000,000

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Exercise Price | $ / shares	$ 39.03
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 17, 2021
Warrants, Exercise Price | $ / shares	$ 14.99
Warrants, Expiration Date	Dec. 15, 2026
Number of Shares Underlying Warrants, Outstanding Total	36,538
Number of Shares Underlying Warrants, Exercisable Total	36,538
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 17, 2021
Warrants, Exercise Price | $ / shares	$ 13.99
Warrants, Expiration Date	Dec. 17, 2026
Number of Shares Underlying Warrants, Outstanding Total	281,047
Number of Shares Underlying Warrants, Exercisable Total	281,047
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 16, 2021
Warrants, Exercise Price | $ / shares	$ 49.99
Warrants, Expiration Date	Feb. 11, 2026
Number of Shares Underlying Warrants, Outstanding Total	65,003
Number of Shares Underlying Warrants, Exercisable Total	65,003
Warrant Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Aug. 07, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	90,743
Number of Shares Underlying Warrants, Exercisable Total	90,743
Warrant Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Aug. 07, 2020
Warrants, Exercise Price | $ / shares	$ 44.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	10,939
Number of Shares Underlying Warrants, Exercisable Total	10,939
Warrant Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 23, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	77,502
Number of Shares Underlying Warrants, Exercisable Total	77,502
Warrant Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 13, 2020
Warrants, Exercise Price | $ / shares	$ 44.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	21,846
Number of Shares Underlying Warrants, Exercisable Total	21,846
Warrant Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 13, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding Total	334,800
Number of Shares Underlying Warrants, Exercisable Total	334,800
Warrant Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jun. 15, 2015
Warrants, Exercise Price | $ / shares	$ 1,509.99
Number of Shares Underlying Warrants, Outstanding Total	15,955
Number of Shares Underlying Warrants, Exercisable Total
Warrants, Expiration Date, Description	Five years after milestone achievement
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Underlying Warrants, Outstanding Total	934,373
Number of Shares Underlying Warrants, Exercisable Total	918,418

Warrants (Details Narrative)

Warrants (Details Narrative)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Warrants
Warrants issued or exercised	0
Purchase of warrants	227,120
Warrants exercise price | $ / shares	$ 39.03

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - Equity Option [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Offsetting Assets [Line Items]
Number of Options, Outstanding, Balance	344,306
Weighted Average Exercise Price, Outstanding, Balance	$ 20.92
Weighted Average Remaining Contractual Term (Years), Outstanding	6 years 4 months 20 days	7 years 6 months 14 days
Aggregate Intrinsic Value, Balance
Number of Options, Forfeited or expired	(93,409)
Weighted Average Exercise Price, Forfeited or expired	$ 5.54
Number of Options, Outstanding, Balance	250,897	344,306
Weighted Average Exercise Price, Outstanding, Balance	$ 26.65	$ 20.92
Aggregate Intrinsic Value, Balance
Number of Options, Exercisable	241,413
Weighted Average Exercise Price, Outstanding, Exercisable	$ 27.45
Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 3 months 25 days
Aggregate Intrinsic Value, Exercisable

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 197	$ 206	$ 498	$ 757
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	3	57	148	188
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 194	$ 149	$ 350	$ 569

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - $ / shares	1 Months Ended	9 Months Ended
	Oct. 28, 2024	Sep. 30, 2024	Dec. 31, 2023
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, award options outstanding number		250,897	344,306
Granted		0
Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted	216,851
Warrants exercise price	$ 26.04
Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, number of shares authorized		818,936
Share based compensation arrangement, number of shares available for grant		564,209
Legacy Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, award options outstanding number		8

Schedule of Components of Lease

Schedule of Components of Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lease cost
Fixed lease cost		$ 553	$ 678	$ 1,349
Variable lease cost	8	203	214	484
Total lease cost	8	756	892	1,833
Cash paid for amounts included in the measurement of lease liabilities	$ 24	$ 2,699	$ 681	$ 3,562
Weighted-average remaining lease term - operating leases		10 years 2 months 12 days		10 years 2 months 12 days
Weighted-average discount rate - operating leases		11%		11%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2024	Aug. 31, 2024
Lease Assignment Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Decrease in right-of-use asset	$ 8.4
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted cash		$ 1.4

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0

Schedule of Computation of Anti

Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options and warrants to purchase common stock	1,185,270	1,526,468	1,185,270	1,526,468
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options and warrants to purchase common stock	250,897	364,975	250,897	364,975
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options and warrants to purchase common stock	934,373	1,161,493	934,373	1,161,493